Statements (56)
Predicate | Object |
---|---|
gptkbp:instanceOf |
drug
|
gptkbp:activeDuring |
linagliptin
|
gptkbp:approves |
gptkb:FDA
|
gptkbp:availability |
prescription only
|
gptkbp:brand |
Tradjenta
|
gptkbp:chemicalFormula |
C25H28N8O2S
|
gptkbp:clinicalTrials |
Phase III
monotherapy or combination therapy effective in lowering blood sugar levels recommended in diabetes treatment guidelines |
gptkbp:commonName |
5 mg once daily
|
gptkbp:contraindication |
allergic reactions
skin reactions pancreatitis hypersensitivity to linagliptin |
gptkbp:developer |
gptkb:Boehringer_Ingelheim
|
gptkbp:dosageForm |
5 mg tablet
|
gptkbp:drugInterdiction |
tablet
long half-life antidiabetic agent increases incretin levels may increase risk of hypoglycemia |
gptkbp:formulation |
oral medication
film-coated tablet |
gptkbp:gestationPeriod |
B
|
gptkbp:hasMuseum |
safety established
|
gptkbp:healthcare |
monitor blood sugar regularly
|
https://www.w3.org/2000/01/rdf-schema#label |
Linagliptin
|
gptkbp:interactsWith |
ACE inhibitors
diuretics other antidiabetic medications |
gptkbp:issuedBy |
oral tablet
|
gptkbp:lastProduced |
2011
|
gptkbp:localBusiness |
widely used worldwide
|
gptkbp:mandates |
improving glycemic control
|
gptkbp:marketedAs |
multiple countries
|
gptkbp:nutritionalValue |
primarily in the liver
|
gptkbp:offers |
varies by region
|
gptkbp:patentExpiration |
2026
|
gptkbp:personalLife |
diet and exercise important
|
gptkbp:researchAreas |
diabetes management
|
gptkbp:researchInterest |
ongoing studies for cardiovascular outcomes
|
gptkbp:safetyFeatures |
generally well tolerated
|
gptkbp:sells |
Tradjenta
|
gptkbp:sideEffect |
headache
diarrhea hypoglycemia nasopharyngitis |
gptkbp:supplyChain |
manufactured_by_Boehringer_Ingelheim
|
gptkbp:targets |
adults with type 2 diabetes
|
gptkbp:triggerType |
DPP-4 inhibitor
|
gptkbp:usedFor |
type 2 diabetes
|
gptkbp:variant |
insulin
metformin sulfonylureas |
gptkbp:waterManagement |
urine
|